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pression was assessed using Beck Depression Inventory
(BDI). Medications were registered. RESULTS: COOP/
WONCA charts showed marked impairment of social ac-
tivities for caregivers of D3 patients (mean score: 2.6 ver-
sus 1.8, 2.1, 1.9, 1.9 and 1.5 for caregivers of respectively
D1, D2, D4, R2 and R1 subjects). Small differences ap-
peared in the other functional aspects. SF-36 showed
comparable mean Physical Component Scores (PCS) for
all caregivers, ranging from 43.5 to 46 according to co-
hort. Caregivers of D3 and/or D4 patients tended to have
lower scores in scales assessing Role limitations due to
Physical problems, Bodily Pain and General Health.
Mean Mental Component Scores (MCS) had the lower
values for caregivers of D3 (42.0) and D2 (44.7) patients
and the highest value for caregivers of R1 subjects (50.9).
Caregivers of D3 patients had the lowest scores in scales
used to score the MCS, namely Social Functioning, Emo-
tional role, Mental Health and Vitality. More than 60%
of caregivers of D3 patients suffered from depression ver-
sus 30% of caregivers of R1, R2 or D1 subjects and 43%
of caregivers of D2 or D4 patients. Results on correlation
with medications and association with cohabitation sta-
tus, age and gender will be presented. CONCLUSION:
moderate/mild to severe dementia has an impact on men-
tal health, physical health and social activities of caregiv-
ers. The impact appears particularly important for care-
givers of moderately demented patients (MMSE 10–14).
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OBJECTIVE: To evaluate the scaling properties of the
Centers for Epidemiologic Studies-Depression Scale (CES-D)
in Israel, Spain, Australia, Brazil, the United States, and
the Russian Federation through the application of the
one-parameter (Rasch) IRT model. METHODS: The
Longitudinal Investigation of Depression Outcomes (LIDO)
is an ongoing observational study in these six countries.
CES-D data (representing symptom-based severity of de-
pression) were gathered from a sample of patients exhib-
iting depressive symptoms, but not necessarily diagnosed
with major depression. Analyses were conducted to as-
sess unidimensionality through goodness-of-fit mean-
square (MNSQ) statistics. The hierarchical structure of
the scale was also examined through the spacing of cate-
gory threshold logit calibrations. RESULTS: Similar pat-
terns were noted across the six countries as shown by the
goodness-of-fit statistics. Three items with MNSQ values
below the recommended range (0.85 indicating redun-
dancy) were identical at each site (I felt depressed, I felt
sad, and I could not shake off the blues). Furthermore,
items that were above the range (1.25 indicating that
they yield responses that do not conform to the response
patterning of most other items) included two of the posi-
tively framed items: I felt that I was just as good as other
people and I felt hopeful about the future. All items cov-
ered the construct well for most language versions, al-
though some gaps in measurement were observed.
Finally, some degree of item overlap/redundancy was
evident in all language versions, with several items
sharing the same location on the underlying construct.
CONCLUSION: Although the CES-D is a commonly
employed measure of depression severity, it may be nec-
essary to take a closer look at its scalability. Such infor-
mation is vital for the appropriate use and interpretation
of multi-center and multi-national data resulting from
this instrument.
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OBJECTIVE: Develop a weighted, global index of safety
(GIS) and compare the safety profiles of olanzapine-treated
patients and patients treated with other antipsychotics
using data from an observational prospective pharma-
coepidemiological study (EFESO). METHODS: A total
of 194 psychiatrists rated through a survey the severity
(from 1 insignificant, to 5 extremely severe) of the most
common adverse events (AE) that occur with antipsycho-
tic treatment. The severity scores were then applied to the
AE occurring in the 2,949 EFESO patients resulting in
per-patient scores. A GIS was calculated for every group
of patients receiving the same treatment by averaging the
per-patient scores. The GIS was compared between the
olanzapine-treated patients and a control group (com-
posed of patients treated with all other antipsychotics) as
well as with patients treated specifically with risperidone
and haloperidol. RESULTS: The GIS calculated from the
control group (4.3) was 72% higher (worse score) than
that calculated for the olanzapine-treated patients (2.5)
(P  .001). The GIS for the risperidone- (3.6) and halo-
peridol- (6.0) treated patients were 44% and 140%
higher than that calculated for the olanzapine-treated pa-
tients (P  .001). CONCLUSIONS: The GIS is a new in-
strument that produces a single, weighted score facilitat-
ing the safety comparison of antipsychotic treatments in
terms of both AE frequency and severity. Application of
the GIS in the EFESO study showed that olanzapine-treated
patients had a significant better (lower) safety index com-
pared to the patients in the control group and compared
specifically to risperidone- and haloperidol-treated pa-
tients.
